Recro Pharma (REPH) Misses Q1 EPS by 5c

Recro Pharma (NASDAQ: REPH) reported Q1 EPS of ($0.71), $0.05 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $13 million.

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Hesai Group (HSAI) Tops Q1 EPS by 8c
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'